Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial

Overview of attention for article published in Malaria Journal, February 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (75th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

twitter: 12 X users

Readers on

mendeley: 97 Mendeley

Summary X

So far, Altmetric has seen 17 X posts from 12 X users, with an upper bound of 29,597 followers.

#ICYMI #Quinoline #neurotoxicity #MefloquineMassTort #veteransuicides #CAF #auspol #UK #Ireland #Commonwealth #VARoyalCommission #tafenoquinedossier https://t.co/57kVDrPFoC

09 Sep 2021

Reply Repost Favourite

RT @StuartMcCarthy_: I'm a CYP2D6 intermediate metaboliser, administered 400 mg/day tafenoquine for three days (total 1200 mg) during one o…

09 Sep 2021

Reply Repost Favourite

RT @StuartMcCarthy_: I'm a CYP2D6 intermediate metaboliser, administered 400 mg/day tafenoquine for three days (total 1200 mg) during one o…

07 Sep 2021

Reply Repost Favourite

I'm a CYP2D6 intermediate metaboliser, administered 400 mg/day tafenoquine for three days (total 1200 mg) during one of the @GSK/@wrair/@AustralianArmy PEP studies. Then diagnosed P vivasx, documented treatment failure. Recommending TQ as a 'workaround' fo

07 Sep 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 13 additional X posts.